Skystar Bio-Pharmaceutical Co., Ltd. (OTCMKTS: SKBI) is a China-based pharmaceutical company engaged in the research, development, manufacturing and commercialization of active pharmaceutical ingredients (APIs), drug intermediates and finished dosage forms. Founded in 2004, the company focuses on small-molecule therapeutics targeting cardiovascular, metabolic and oncology indications. Its product portfolio includes approved generic formulations for hypertension and diabetes, as well as proprietary drug candidates, among them a novel small-molecule oncology agent currently in Phase II clinical trials.
The company’s vertically integrated model spans discovery chemistry, process development and large-scale production. Skystar’s R&D center in Shanghai houses state-of-the-art laboratories staffed by over 150 scientists specializing in medicinal chemistry, pharmacology and formulation. Manufacturing operations, located in Jiangsu province, operate under cGMP-certified facilities that support batch production of APIs and finished pharmaceuticals with stringent quality control and regulatory compliance.
Skystar has built a global commercial footprint through strategic partnerships and distribution agreements. Finished products and active ingredients are exported to more than 30 countries across Asia, Europe, Latin America and the Middle East. Domestically, the company serves hospitals, retail pharmacies and online channels, while investing in digital marketing and telemedicine collaborations to enhance market reach and patient access in emerging regions.
Under the leadership of Chairman and CEO Li Jun, a pharmaceutical industry veteran with over 25 years of experience, Skystar has evolved from a regional API supplier into a diversified biopharmaceutical enterprise. The executive team includes CFO Wang Mei, who oversees financial strategy and investor relations, and Chief Scientific Officer Dr. Lin Chen, who directs clinical development and regulatory affairs. Skystar continues to prioritize innovation, quality and global expansion as it advances its pipeline and strengthens its competitive position.
AI Generated. May Contain Errors.
Free SKBI Stock Alerts